Cargando…

Methionine restriction sensitizes cancer cells to immunotherapy

Detalles Bibliográficos
Autores principales:	Lu, Weiqin, Luo, Yongde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631477/ https://www.ncbi.nlm.nih.gov/pubmed/37803877 http://dx.doi.org/10.1002/cac2.12492

Ejemplares similares

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

Combined immunotherapy for advanced prostate cancer: Empowering the T cell army
por: Suleman, Sufyan, et al.
Publicado: (2017)

A ‘fit’ microbiota to potentiate cancer immunotherapy
por: Rescigno, Maria
Publicado: (2015)

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

Linearly Polarization-Sensitive Perovskite Photodetectors
por: Sun, Jie, et al.
Publicado: (2023)

From Tpex to Tex: a journey through CD8(+) T cell responses in cancer immunotherapy
por: Messmer, Julia M., et al.
Publicado: (2023)

Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
por: Ullrich, Evelyn, et al.
Publicado: (2022)

Transcriptional suppression of CD8(+) T cell exhaustion for improving T cell immunotherapy
por: Yang, Xue, et al.
Publicado: (2021)

Methionine Restriction and Cancer Biology
por: Wanders, Desiree, et al.
Publicado: (2020)

Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy
por: Du, Songtao, et al.
Publicado: (2023)

An effective platform for cancer immunotherapy: pooled knockin targeting for genome engineering
por: Jin, Ke, et al.
Publicado: (2020)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
por: Almeida, Catarina R., et al.
Publicado: (2021)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

CD5: from antiquated T cell marker to immunotherapy’s new hope
por: Schwarz, Sandra, et al.
Publicado: (2023)

New strategy for cancer immunotherapy: using live engineered bacteria for metabolic modulation
por: Li, Tong, et al.
Publicado: (2021)

Doubling down with CAR-T cell cancer immunotherapy: a two-step recognition circuit enables discrimination between target antigen high and low cancer cells
por: Charo, Jehad, et al.
Publicado: (2021)

A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination
por: Rafi, Mohammad A., et al.
Publicado: (2015)

METABOLIC CONSEQUENCES OF METHIONINE REDOX IN METHIONINE RESTRICTION
por: Thyne, Kevin, et al.
Publicado: (2019)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Cytotoxic FCER1G(+) innate-like T cells: new potential for tumour immunotherapy
por: Morrish, Emma, et al.
Publicado: (2022)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

Going only half the way: cell cycle exit after the G1 restriction point
por: Müller, Lisa, et al.
Publicado: (2023)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Safety and efficacy of toripalimab in advanced gastric cancer: A new clinical trial bringing hope for immunotherapy in gastric cancer
por: Qiu, Haibo
Publicado: (2020)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs
por: Zhang, Zhihui, et al.
Publicado: (2021)

Likely a matter of time for Amyloid-β immunotherapy
por: Cunha, Andreia
Publicado: (2021)

Can cannibalizing cancer cells challenge classic cell death classification?
por: Walton, Emma Louise
Publicado: (2017)

Cancer Environment Immunotherapy: targeting TGF-β finds its way towards tissue healing and vasculature remodeling
por: Jin, Ke, et al.
Publicado: (2021)

NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity
por: Barros-Martins, Joana, et al.
Publicado: (2022)

You cannot oxidize what you cannot reach: Oxidative susceptibility of buried methionine residues
por: Kulczyk, Arkadiusz W., et al.
Publicado: (2022)

Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer
por: Kurniawan, Henry, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1e6l3ol7bo06cq79or2ugitofa